Biocept's Target Selector Platform Featured in Two Poster Presentations at the IASLC 19th World Conference on Lung Cancer
Details for the poster presentations are as follows:
Title: Analysis and Monitoring CTCs and ctDNA in CSF Demonstrates Clinical Concordance in Tesevatinib Treated NSCLC Patients with LM
Session Category/Title: P1.01-Advanced NSCLC
Session Date and Time:
Location:
Link to Abstract
Title: Clinical Utility of Circulating Tumor Cell (CTC) Analysis Using Target Selector™ in Metastatic NSCLC Chemotherapy Patients
Session Category/Title: P2.01-Advanced NSCLC
Session Date and Time:
Location:
Link to Abstract
"The interim results of our analysis of circulating tumor cells (CTC) in patients with advanced stage lung cancer receiving chemotherapy suggest that CTC enumeration may have prognostic and predictive potential for assessing therapeutic benefit," said
"The ability to evaluate tumor markers in the cerebrospinal fluid (CSF) of lung cancer patients is potentially an important use of liquid biopsy when metastases to the central nervous system is suspected or diagnosed," said
"We believe that presenting data highlighting the performance of our Target Selector™ assays at major medical conferences such as this year's
About the IASLC 19th
The WCLC is the world's largest meeting dedicated solely to lung cancer and other thoracic malignancies, and is expected to convene over 7,000 researchers, physicians, specialists, patients, advocates and industry members from around the world. The WCLC's scientific program features a line-up of global leaders in the field. Presentations focus on cutting-edge science, including the latest breakthroughs in targeted therapies and immunotherapies; advances in screening, early detection and staging; prevention and smoking cessation efforts; patient advocacy initiatives; and much more. Collaboration across disciplines and borders is a meeting highlight. The WCLC's scientific program is available to review online.
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, the versatility and clinical utility of our proprietary liquid biopsy platform, and our ability to increase physician adoption of our liquid biopsy platform , such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
View original content with multimedia:http://www.prnewswire.com/news-releases/biocepts-target-selector-platform-featured-in-two-poster-presentations-at-the-iaslc-19th-world-conference-on-lung-cancer-300707838.html
SOURCE
Investor Contact: LHA Investor Relations, Jody Cain, Jcain@lhai.com, 310-691-7100, Media Contact: Trevelino/Keller, Colleen Murphy, cmurphy@trevelinokeller.com, 404-214-0722, Ext. 109